Opus Genetics (NASDAQ:IRD – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01, Zacks reports. The company had revenue of $3.87 million for the quarter, compared to the consensus estimate of $1.17 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 59.72%.
Opus Genetics Trading Down 5.3 %
NASDAQ IRD traded down $0.06 on Wednesday, reaching $1.08. The company had a trading volume of 145,459 shares, compared to its average volume of 170,476. Opus Genetics has a 52 week low of $1.07 and a 52 week high of $3.40.
Analysts Set New Price Targets
Separately, HC Wainwright began coverage on Opus Genetics in a research report on Wednesday. They issued a “buy” rating and a $8.00 price objective for the company.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
- Five stocks we like better than Opus Genetics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Rocket Lab is the Right Stock for the Right Time
- What is the Euro STOXX 50 Index?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Compound Interest and Why It Matters When Investing
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
